hDC-sign binding peptides
US9481724B2 · kind B2 · utility
5Cited by
0References
21Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 10, 2012 |
| Grant date | Nov 1, 2016 |
| Priority date | — |
| Expiry date | Jul 15, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Polypeptides that bind to DC-SIGN and/or its homologues and methods for using such peptides for the treatment of various disorders are described. DC-SIGN and its homologues are receptors that bind IgG antibodies or Fc fragments and mediate intravenous immunoglobulin (IVIG)-related reversal of inflammation associated with various immune disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.